Cartoonist Scott Adams—creator of the iconic “Dilbert” comic strip—publicly appealed for help to receive a critical, newly approved cancer drug following what he described as a delay by his medical provider.
Adams revealed he was approved for the intravenous therapy but said his healthcare facility had failed to schedule the infusion, despite his condition rapidly declining.
In response, senior members of the Trump administration, including Robert F. Kennedy Jr., the Secretary of Health & Human Services, and Dan Scavino, Deputy Chief of Staff, offered assistance, stating that President Donald Trump had directed the matter be tracked immediately.
The treatment in question, a radioligand therapy approved by the FDA, is designed for advanced prostate cancer and is considered potentially life-extending for some patients. Adams, who shared his diagnosis publicly earlier this year, described his condition as urgent and marked by daily pain and mobility challenges.
Adams thanked the administration for its rapid response and said he hoped the push would ensure his infusion is scheduled promptly. At the same time, he and his advocates stressed the broader issue of treatment access and delays in the health system for patients with aggressive illness.
As the case gains attention, it underscores how high-profile appeals can spur administrative action—and raises questions about the standard process for securing cutting-edge treatments in serious medical cases.